Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canada was plagued by Covid shot supply shortages earlier this year after it struggled to obtain doses manufactured in other countries.

Moderna reaches deal with Canada to build 'state-of-the-art' Covid vaccine manufacturing plant after shortages

The short-term thesis for investing in Moderna is the belief that the company will continue to profit from its COVID-19 vaccine because of booster shots.

Moderna: Only For Aggressive Investors

Here's Who's Making a $1 Billion Bet on Moderna

Moderna Inc (NASDAQ: MRNA), a company founded in 2010, is now worth more than the 129-year old Merck & Co., Inc (NYSE: MRK) in terms of market capitalization. What Happened: Moderna's shares spiked Monday amid a string of positive news including being granted provisional registration by the Australian Therapeutic Goods Administration for its COVID-19 vaccine.

Moderna Is Now Valued Higher Than 130-Year Old Vaccine Giant Merck

BioNTech SE

Novavax

Coronavirus fears sparked a rally in the shares of the major vaccine makers.

Why Moderna, BioNTech, and Novavax Stock Soared Today

Pfizer

Vir Biotechnology

Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?

3 Vaccine Stocks for the Next Decade

Moderna Inc. (NASDAQ:MRNA) shares rallied higher Monday after vaccine stocks continue trading higher with Delta variant worries. The company also reportedly received Swiss approval for the use of the vaccine in 12 to 17 year olds.

Moderna Continues To Fly Higher: What's Next?

Shares of Moderna and BioNTech both skyrocketed on Monday amid growing enthusiasm over technology used in their coronavirus vaccines and its potential to help fight other ailments like cancer and malaria.

Moderna and BioNTech shares skyrocket amid talk of mRNA treatments for cancer, malaria

Moderna, the almost 11 year old company that created a 95% effective pandemic ending vaccine in less than a year, is now worth more than Merck.

Moderna spikes 19% amid a flood of encouraging vaccine news, surpassing Merck in market value

NetEase

U.S. indices had a mixed day of trading Monday as investors weigh Friday's better-than-expected jobs data, infrastructure news and recent earnings. The Invesco QQQ Trust Series 1 (NASDAQ: QQQ) gained 0.18% to $368.73

Moderna And Netease Gain In A Mixed Day For The Markets

Moderna Inc. (NasdaqGS: MRNA) surged Monday after the company's Covid-19 vaccine was granted a provisional adult authorization in Australia, lifting biotechnology sector-related exchange traded funds. On Monday, the VanEck Vectors Biotech ETF (BBH) rose 3.0% and the iShares Nasdaq Biotechnology ETF (IBB) gained 2.3%.

Moderna Vaccine Is Granted Authorization in Australia

Etsy

Lyft

Uber

Last week was another busy earnings week for Wall Street, so let's review some of the highlights in this version of Market360. The post Major Earnings Results from This Week appeared first on InvestorPlace.

Major Earnings Results from This Week

Johnson & Johnson

There's major potential for all of these biotech stocks, especially after full FDA approval, but this one stands to be one of the top winners. The post Why These Biotech Stocks Are Soaring appeared first on InvestorPlace.

Why These Biotech Stocks Are Soaring

Shares of Moderna Inc. MRNA, +11.04% were up 9.4% in trading on Monday after the company said its COVID-19 vaccine has been granted a provisional authorization in Australia to adults who are at least 18 years old. Australia has purchased 10 million doses of Moderna's vaccine for 2021 and has the option to purchase an additional 15 million doses in 2022.

Moderna's COVID-19 vaccine is granted authorization in Australia

Moderna Inc (NASDAQ: MRNA) is trading higher Monday as growing COVID-19 concerns lift vaccine makers. The company's COVID-19 vaccine was also granted provisional registration by the Australian Therapeutic Goods Administration.

What's Going On With Moderna's Stock Today?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Australian Therapeutic Goods Administration grants provisional registration for Moderna's COVID-19 vaccine.

Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna's COVID-19 Vaccine

Moderna Is A Winner In COVID-19 Vaccines, But What's Next?

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session.

PreMarket Prep Stock Of The Day: Moderna

Moderna Inc (NASDAQ:MRNA) shares are experiencing weakness for a second straight session following the release of its quarterly results. The Moderna Analyst: Oppenheimer analyst Hartaj Singh downgraded Moderna shares from Outperform to Perform.

If Moderna Is 'Executing Superbly' On Its COVID-19 Vaccine Portfolio, Why Is This Analyst Downgrading The Stock?

One analyst thinks the stock is pricing-in a tremendous amount of future revenue. Another thinks the biotech's value has already been captured in its share price.

Moderna Had Admirers. Still, the Stock Gets Hit With Downgrades.

Moderna, Inc. is a biotechnology company developing a new revolutionary type of transformative medicines based on messenger RNA. The company expects to prepare for the endemic phase of COVID-19 in the year 2023. I will show later that most analysts have not taken into account the endemic phase.

Moderna: My DCF Model Reveals An Implied Share Price Of $583-$771

The level of protection provided by Moderna's COVID-19 vaccine is nearly as high at six months as it is right after vaccination, but the company said vaccinated people will still need booster shots before the end of the year.

Moderna presses for COVID-19 boosters as federal health officials warm to an extra dose for some people

Analysts think Moderna stock is too high after quadrupling in 2021. If it keeps beating revenue expectations, its shares have further to go.

After A 325% Rise, Here's Why Moderna Stock Has Further To Run

Shares of Moderna Inc. fell 1.7% in premarket trading Friday, after the biotechnology company with one of the three COVID-19 vaccines granted emergency use authorization in the U.S. was downgraded by a long-time bullish analyst, saying that "the dream is alive, but valuation moves us to the sidelines. On Thursday, the company had reported a big second-quarter profit beat, but the stock pulled back 0.7% after soaring 20.9% the previous two days to a record close on Wednesday.

Moderna stock extends pullback after long-time bullish analyst moves to sidelines on valuation concerns

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna named the number one company on Fast Company's 2021 Best Workplaces for Innovators list

News for Moderna Stock (MRNA)